The study is a randomized controlled study, designed to test the efficacy and safety of a new treatment modality for the prevention of tumor recurrence in superficial bladder cancer.~Patients must have their tumors surgically resected prior to study enrollment, and undergo a series of tests to prove their bladder is now free of tumor. Eligible patients will be randomly assigned to one of 2 treatment arms:~A combination of bladder wall heating and local chemotherapy (Synergo)~Bacillus Calmette-Guérin (BCG)~Patients will be treated during the first year of the study, and will be followed up for a total of 2 years. The follow up will include a visual evaluation of the patient's bladder by cystoscopy, a cytological examination of the urine (to look for malignant cells) and other additional exams. The patients' general welfare will be monitored through out the study.~The aim of this study is to compare the efficacy and safety of the novel treatment (Synergo) to that of the well-known BCG
The study is designed to compare the efficacy and safety of 2 treatment types for the prevention of tumor recurrence of superficial bladder cancer:~A combination of bladder wall heating and local chemotherapy (Synergo)~Bacillus Calmette-Guérin (BCG)